Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 12, 2024 16:15 ET
|
Biora Therapeutics, Inc.
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from...
Biora Therapeutics Announces Funding Agreement with Existing Investors
August 12, 2024 16:05 ET
|
Biora Therapeutics, Inc.
$16 million multiple-draw facility to be used as a bridge to anticipated pharma partnership
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
August 08, 2024 16:30 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and...
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
August 06, 2024 08:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
July 18, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired.
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
July 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
July 01, 2024 08:00 ET
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
June 11, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024 16:05 ET
|
Biora Therapeutics, Inc.
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.